Skip to content

Immune Responses to COVID-19 Booster Vaccine With and Without Ganoderma Lucidum Spore Powder

Effects of oral wall-removed Ganoderma lucidum spore powder on antibody levels after injection of COVID-19 vaccine booster

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078082
Enrollment
Unknown
Registered
2023-11-28
Start date
2021-10-09
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group:Take Ganoderma lucidum spore powder
Control group:None

Sponsors

Zhejiang Provincial Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy people aged 40-60; the new crown vaccine has been vaccinated for more than 6 months; the informed consent of the subjects is obtained and the informed consent is signed.

Exclusion criteria

Exclusion criteria: Those who cannot eat orally or take the health food as prescribed; pregnant or breastfeeding women; those who are intolerant or allergic to the health food; those who have unclear complaints; those who take food or medicine related to the health food in a short period ; Fever before vaccination, armpit body temperature > 37.0 ?; physical examination showed any obvious abnormalities in heart, lung, skin, and pharynx; various acute diseases or acute attacks of chronic diseases in the past 7 days; history of allergy to vaccines or vaccine components, severe adverse reactions to the vaccine, such as urticaria, dyspnea, angioneurotic edema, or abdominal pain; received immune globulin and other blood products within 3 months before vaccination; received immunosuppressant therapy within the past 6 months , cytotoxic drug therapy, inhaled corticosteroid therapy (excluding corticosteroid spray therapy for allergic rhinitis, topical corticosteroid therapy for acute uncomplicated dermatitis); epilepsy (excluding febrile epilepsy), history of convulsions or convulsions, or Family history of psychiatric illness; autoimmune disease or immunodeficiency; physician-diagnosed coagulation abnormalities (eg, coagulation factor deficiencies, coagulation disorders, thrombocytopenia).

Design outcomes

Primary

MeasureTime frame
Neutralization inhibition rate;

Secondary

MeasureTime frame
Blood biochemical indicators;Immunological indicators;Efficacy indicators;

Countries

China

Contacts

Public ContactZhao Dong

Zhejiang Provincial Center for Disease Control and Prevention

dzhao@cdc.zj.cn+86 159 5801 4972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026